ClinOne and Kayentis in pact to address DCT, hybrid trial needs

ClinOne, which develops trial site platforms, and Kayentis have inked a partnership deal in a move to address the growing needs of decentralized clinical trials and hybrid or virtual component trials.

The pact will leverage ClinOne’s adaptive clinical trial experience with Kayentis’ background in clinical outcome assessment and DCT solutions, the companies said in a Jan. 10 press release.

Financial terms of the collaboration weren’t disclosed.

The two said together they will build a web portal, an integrated provisioned devices solution and an account management system that would provide a single-access point for all their services.

Decentralized and virtual clinical trials emerged from disruptions caused by the COVID-19 pandemic as the preferred choice for drug developers fueled by new technologies. GlobalData estimates cited in the release said there were about 1,300 decentralized trials and/or virtual component trials in 2022. That represented a jump of 28% compared to 2021.

“Kayentis is collaborating with ClinOne to provide a complete range of services in DCT, including eConsent, patient portal and recruitment tools,” Guillaume Juge, chief executive of Kayentis, said in the release. “It not only has complementary ‘best of breed’ solutions, it also has similar values and views of the market, with the common goal of better serving sponsors, making the operation of sites and the lives of patients easier.”